NEWS | BEAM Alliance

NEWS

UNION therapeutics Announces Successful Phase 1 Study Completion with ATx201

UNION therapeutics Announces Successful Phase 1 Study Completion with ATx201

COPENHAGEN, OCTOBER 22, 2018 – UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today announced positive results from a Phase 1 Sensitization Study in 240 healthy adult volunteers with ATx201. The study was conducted in the US under IND as a randomized and placebo-controlled study. In comparing the active group to placebo, no signs of sensitization were observed, and no subjects showed any signs of unexpected adverse events.

Full PR available here